About Galmed Pharmaceuticals (NASDAQ:GLMD)
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448
Debt
Debt-to-Equity RatioN/A
Current Ratio4.99%
Quick Ratio4.99%
Price-To-Earnings
Trailing P/E Ratio-6.13
Forward P/E Ratio-7.81
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.09 million
Price / Sales85.13
Cash FlowN/A
Price / CashN/A
Book Value$1.24 per share
Price / Book4.85
Profitability
EPS (Most Recent Fiscal Year)($0.98)
Net Income$-12,290,000.00
Net Margins-1,133.55%
Return on Equity-133.50%
Return on Assets-94.64%
Miscellaneous
Employees16
Outstanding Shares15,440,000
Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions
What is Galmed Pharmaceuticals' stock symbol?
Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."
How were Galmed Pharmaceuticals' earnings last quarter?
Galmed Pharmaceuticals (NASDAQ:GLMD) posted its quarterly earnings data on Tuesday, March, 13th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.04. The biopharmaceutical company earned $0.27 million during the quarter, compared to analysts' expectations of $0.28 million. Galmed Pharmaceuticals had a negative net margin of 1,133.55% and a negative return on equity of 133.50%. View Galmed Pharmaceuticals' Earnings History.
When is Galmed Pharmaceuticals' next earnings date?
What price target have analysts set for GLMD?
4 brokerages have issued 1 year target prices for Galmed Pharmaceuticals' shares. Their forecasts range from $14.00 to $32.00. On average, they anticipate Galmed Pharmaceuticals' stock price to reach $22.25 in the next year. View Analyst Ratings for Galmed Pharmaceuticals.
What are Wall Street analysts saying about Galmed Pharmaceuticals stock?
Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (1/11/2018)
- 2. Maxim Group analysts commented, "Galmed reported 3Q17, spending just $2.8M and closing the period with $9M in cash. Management was clear that with their efforts to preserve cash, they have runway through 2018 and through catalysts; data from both ARRIVE and ARREST studies." (11/9/2017)
Who are some of Galmed Pharmaceuticals' key competitors?
Some companies that are related to Galmed Pharmaceuticals include Mersana Therapeutics (MRSN), Corbus Pharmaceuticals (CRBP), GTX (GTXI), Dermira (DERM), Clearside Biomedical (CLSD), Unum Therapeutics (UMRX), Strongbridge Biopharma (SBBP), Paratek Pharmaceuticals (PRTK), Merus (MRUS), Kadmon (KDMN), Catalyst Biosciences (CBIO), Durect (DRRX), American BriVision (Holding) (ABVC), Seres Therapeutics (MCRB) and Celyad (CYAD).
Who are Galmed Pharmaceuticals' key executives?
Galmed Pharmaceuticals' management team includes the folowing people:
- Mr. Allen Baharaff, Chief Exec. Officer, Pres and Director (Age 53)
- Mr. Yohai Stenzler CPA, Chief Financial Officer and Controller (Age 35)
- Mr. Guy Nehemya, VP of Operations (Age 33)
- Dr. Liat Hayardeny Ph.D., MBA, Chief Scientific Officer (Age 51)
- Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 35)
Has Galmed Pharmaceuticals been receiving favorable news coverage?
Media stories about GLMD stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of 0.24 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.05 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Galmed Pharmaceuticals?
Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Galmed Pharmaceuticals' stock price today?
One share of GLMD stock can currently be purchased for approximately $6.01.
How big of a company is Galmed Pharmaceuticals?
Galmed Pharmaceuticals has a market capitalization of $95.39 million and generates $1.09 million in revenue each year. The biopharmaceutical company earns $-12,290,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Galmed Pharmaceuticals employs 16 workers across the globe.
How can I contact Galmed Pharmaceuticals?
Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.
MarketBeat Community Rating for Galmed Pharmaceuticals (GLMD)
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Galmed Pharmaceuticals (NASDAQ:GLMD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Galmed Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.25, suggesting that the stock has a possible upside of 270.22%. The high price target for GLMD is $32.00 and the low price target for GLMD is $14.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.25 | $22.25 | $20.75 | $17.00 |
| Price Target Upside: | 270.22% upside | 259.45% upside | 105.85% upside | 84.78% upside |
Galmed Pharmaceuticals (NASDAQ:GLMD) Consensus Price Target History
Galmed Pharmaceuticals (NASDAQ:GLMD) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Galmed Pharmaceuticals (NASDAQ:GLMD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Galmed Pharmaceuticals (NASDAQ GLMD) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 17.69%
Galmed Pharmaceuticals (NASDAQ GLMD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Galmed Pharmaceuticals (NASDAQ GLMD) News Headlines
| Source: |
|
Galmed Pharmaceuticals (NASDAQ:GLMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Galmed Pharmaceuticals (NASDAQ:GLMD) Income Statement, Balance Sheet and Cash Flow Statement
Galmed Pharmaceuticals (NASDAQ GLMD) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
